Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial

J Rheumatol. 1985 Aug;12(4):735-7.


A double blind placebo controlled trial was carried out over a 6-month period on 17 patients with ankylosing spondylitis (AS) to assess the effect of the second line antirheumatic drug, D-penicillamine. The patients included 13 with peripheral joint involvement. No significant improvement over placebo was detected in a variety of clinical and laboratory indices in the patients receiving active treatment. This controlled trial would not support a use for penicillamine in AS.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Penicillamine / adverse effects
  • Penicillamine / therapeutic use*
  • Random Allocation
  • Spondylitis, Ankylosing / drug therapy*


  • Penicillamine